The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

ASCO 2019 | Biggest obstacles in lung cancer therapy

Name: Biggest obstacles in lung cancer therapy
Uploaded: 2019-06-02T00:00:00Z
Duration: 59 s
Description: Roy Herbst, MD, PhD, FACP, FASCO, of Yale University, New Haven, CT, tells us about the difficulties the heterogeneity of lung cancer causes in the treatment of the disease. This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

Roy Herbst • 2 Jun 2019

ASCO 2019

Lung Cancer

Roy Herbst, MD, PhD, FACP, FASCO, of Yale University, New Haven, CT, tells us about the difficulties the heterogeneity of lung cancer causes in the treatment of the disease. This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.